GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

GSK Plc agreed to buy an experimental medicine to treat liver diseases for as much as $2 billion as the UK drugmaker seeks to ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

British pharmaceutical company GSK(GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...